Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tsubomi Trial of sacituzumab tirumotecan plus pembrolizumab in recurrent ovarian clear cell carcinoma
jRCT2031260646Phase 2Not yet recruiting
- Start
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and pembrolizumab in clear cell ovarian cancer, sponsored by none. Primary endpoint: Objective response rate. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
clear cell ovarian cancer
Beyond the preview
Go deeper on jRCT2031260646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260646.